Loading
FcRH5 is a surface protein found almost only on B cells and myeloma plasma cells, which makes it a target for T-cell engaging antibodies in multiple myeloma.
FCRL5 encodes Fc receptor-like 5, a B-lineage surface receptor expressed on mature B cells and retained on plasma cells; on myeloma cells expression is near-universal and higher than on normal counterparts, in part through 1q21 gain where the gene sits. Cevostamab, a FcRH5 x CD3 bispecific antibody, is in late-stage trials for relapsed and refractory multiple myeloma; no approval names the antigen yet.
In plain words · FcRH5 is a surface protein found almost only on B cells and myeloma plasma cells, which makes it a target for T-cell engaging antibodies in multiple myeloma.
FcRH5 is a surface protein found almost only on B cells and myeloma plasma cells, which makes it a target for T-cell engaging antibodies in multiple myeloma.
A type I transmembrane protein with immunoglobulin-like domains that modulates B-cell receptor signalling; its restricted lineage expression, like BCMA and GPRC5D, is what makes it a T-cell redirection target.
No product in this corpus aims at FcRH5 (FCRL5) yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Lineage antigen shared with normal lymphoid tissue cells: HPA blood lineage lineage enriched at or above 25 nTPM, and 1 antibody (Cevostamab) aim at it, so normal cells of the lineage are hit too. HPA FCRL5: RNA tissue enriched (lymphoid tissue 34 nTPM); blood lineage lineage enriched (B-cells 14 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Multiple myeloma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas FCRL5 tissue; Human Protein Atlas FCRL5 pathology; Open Targets ENSG00000143297 associations
First described 2001. Earliest sequence paper UniProt cites for the protein: Nakayama et al, Biochem. Biophys. Res. Commun, 2001, "BXMAS1 identifies a cluster of homologous genes differentially expressed in B cells". Source.
What a pathology or genomic report can say about this target, each with the thresholds approvals use.
A type I transmembrane protein with immunoglobulin-like domains that modulates B-cell receptor signalling; its restricted lineage expression, like BCMA and GPRC5D, is what makes it a T-cell redirection target.
RNA: tissue enriched (lymphoid tissue 34 nTPM), detected in some normal tissues. Blood: lineage enriched (B-cells 14 nTPM).
No normal tissue stained high.
No cancer sample stained medium or high.
HPA FCRL5 tissue · HPA FCRL5 pathology · HPA protein class: CD markers
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FcRH5" OR ABSTRACT:"FcRH5" OR TITLE:"FCRL5" OR ABSTRACT:"FCRL5" OR TITLE:"FCRH5" OR ABSTRACT:"FCRH5" OR TITLE:"IRTA2" OR ABSTRACT:"IRTA2" OR TITLE:"CD307e" OR ABSTRACT:"CD307e" OR TITLE:"Fc receptor-like 5" OR ABSTRACT:"Fc receptor-like 5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FcRH5 (FCRL5), not a curated reading list.
Shares Cevostamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Cevostamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares FcRH5 expression, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag surface-antigen.
Shares FcRH5 expression, Relapsed or refractory multiple myeloma, Multiple myeloma and the tag surface-antigen.
Shares Cevostamab, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.